Literature DB >> 9355169

Effect of antidepressant therapy on health care utilization and costs in primary care.

T W Croghan1, T J Lair, L Engelhart, W E Crown, C Copley-Merriman, C A Melfi, R L Obenchain, D P Buesching.   

Abstract

OBJECTIVE: Four groups of patients receiving different antidepressant drugs in a primary care setting were compared in terms of duration of antidepressant therapy and health and mental health care utilization and costs.
METHODS: A retrospective analysis of the medical and pharmacy claims of an employed population and their families was conducted. A total of 1,242 patients with a diagnosis of depression were included in the analyses. The four antidepressant cohorts were fluoxetine (N = 799), trazodone (N = 89), the tricyclics amitriptyline and imipramine (N = 104), and the secondary amine tricyclics desipramine and nortriptyline (N = 250). The primary outcome measures were total health care charges, total charges for mental health services, and the pattern of antidepressant use. Secondary measures included charges for outpatient care and pharmacy and the number of outpatient visits. Data analysis involved use of two-stage multivariate regression modeling known as sample selection models.
RESULTS: Patients taking fluoxetine achieved higher rates of continuous use for at least six months compared with those taking the other drugs. After selection bias due to observed and unobserved characteristics and other confounding variables was adjusted for, no significant differences were found between drug cohorts in total medical charges.
CONCLUSIONS: Improvements in the process of care at no apparent increase in total charges appear possible through appropriate medication therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355169     DOI: 10.1176/ps.48.11.1420

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  13 in total

1.  Initial treatment choice in depression: impact on medical expenditures.

Authors:  E T Edgell; T R Hylan; J R Draugalis; S J Coons
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  A Case Report of Drug-Induced Dermatitis With Weekly Fluoxetine.

Authors:  Sanjay Gupta; Barbara Lentz; Bradford L. Frank
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-04

3.  Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy.

Authors:  R L Obenchain; C A Melfi; T W Croghan; D P Buesching
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 4.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 5.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

6.  Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study.

Authors:  Hillary R Bogner; Julia Y Lin; Knashawn H Morales
Journal:  Int J Psychiatry Med       Date:  2006       Impact factor: 1.210

7.  Antidepressant selection and use and healthcare expenditures. An empirical approach.

Authors:  W H Crown; T R Hylan; L Meneades
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

8.  A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Patrick W Sullivan; Robert Valuck; Joseph Saseen; Holly M MacFall
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.

Authors:  Ya-Chen Tina Shih; Nebiyou B Bekele; Ying Xu
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.